Effects of p450 Polymorphisms on the Clinical Outcomes of Gefitinib Treatment in Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer
- 1 December 2022
- journal article
- research article
- Published by Mary Ann Liebert Inc in Genetic Testing and Molecular Biomarkers
- Vol. 26 (12), 582-588
- https://doi.org/10.1089/gtmb.2022.0070
Abstract
Aims: In this study, we determined whether different genotypes of drug-metabolizing enzymes are associated with the therapeutic effects of gefitinib in non-small cell lung cancer (NSCLC). Methods: A retrospective analysis of 112 patients with stage III or IV NSCLC was performed. The clinical characteristics of these patients, including progression-free survival (PFS), outcome of gefitinib treatment, and relationship between the genotypes of rs1065852/rs2242480 and prognosis, were analyzed. Results: The rs1065852 CT/TT genotype was associated with worse prognosis than the CC type (p = 0.0306), and the median PFS was lower than that with the CC type (287 days vs. 350 days). Compared with those with CC+CC genotypes, individuals carrying T alleles (CT/TT+CT/TT) at rs1065852/rs2242480 had a poorer prognosis, and the median PFS of CT/TT+CT/TT at rs1065852/rs2242480 was significantly lower than that of the CC+CC type (188 days vs. 444.5 days). Conclusions: Genotypes of the drug-metabolizing enzymes rs1065852 and rs2242480 have an impact on the prognosis of patients with NSCLC treated with gefitinib.Keywords
This publication has 27 references indexed in Scilit:
- Functional Gene Variants of CYP3A4Clinical Pharmacology & Therapeutics, 2014
- Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancerBMC Cancer, 2012
- CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 TrialJNCI Journal of the National Cancer Institute, 2012
- Cytochrome P450 variations in different ethnic populationsExpert Opinion on Drug Metabolism & Toxicology, 2012
- Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor MutationsJournal of Thoracic Oncology, 2011
- Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidenceLung Cancer, 2011
- Staging of non-small cell lung cancer (NSCLC): A reviewRespiratory Medicine, 2010
- Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 EnzymesClinical Cancer Research, 2007
- Exploring the Relationship Between Expression of Cytochrome P450??Enzymes and Gefitinib PharmacokineticsClinical Pharmacokinetics, 2006
- Single-Dose Clinical Pharmacokinetic Studies of GefitinibClinical Pharmacokinetics, 2005